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Abstract This study investigated whether weekly teripara-
tide (TPTD) injections are as effective as daily teriparatide
injections for the treatment of stage 3 bisphosphonate-
related osteonecrosis of the jaws (BRONJ) and compared
serum markers of bone turnover between the two treatment
regimens. Daily TPTD treatment has recently been reported
to be effective for BRONJ, but there are no reports describ-
ing the effectiveness of weekly TPTD injections. We report
two patients with stage 3 BRONJ. One patient was success-
fully treated with weekly TPTD injections and the other
with daily TPTD injections. Changes in the levels of serum
N-telopeptide of type I collagen (s-NTX) and serum N-
terminal propeptide of type I collagen (P1NP) were studied.
Two patients with stage 3 BRONJ that was refractory to
conservative treatment were treated with TPTD. Their med-
ical records were reviewed and the patients were inter-
viewed. There was complete mucosal coverage of the
intraoral defects after 3 months of TPTD treatment in both
patients. Progressive bone regeneration in an area of man-
dibular fracture was identified after 4 months of treatment.
The s-NTX level increased slightly in both patients. This is
the first report of successful treatment of stage 3 BRONJ
with weekly TPTD injections. Either daily or weekly TPTD
injections may effectively treat stage 3 BRONJ and should
be considered before or perhaps even in lieu of undertaking
major resection and reconstruction.
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Introduction
Nitrogen-containing bisphosphonates (N-BP) are prescribed
for the treatment of bone diseases such as osteoporosis, mul-
tiple myeloma, cancer metastases, and Paget’s disease. How-
ever, bisphosphonate-related osteonecrosis of the jaws
(BRONJ) has been reported as a rare complication. BRONJ
occurs at a much higher rate in patients receiving intravenous
N-BPs for cancer treatment versus oral N-BPs. The incidence
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of BRONJ in patients treated for osteoporosis is low at 0.1 %,
but the incidence of BRONJ in cancer patients treated with
high doses of intravenous N-BP is higher at 3 to 10 % [1].
Currently, conservative treatment is recommended for
BRONJ, in accordance with the American Association of Oral
and Maxillofacial Surgeons (AAOMS) Position Paper [2].
Recently, however, it has been reported that daily parathyroid
hormone treatment is effective for BRONJ. Weekly teripara-
tide (TPTD; human parathyroid hormone peptide 1–34) injec-
tions have been used to treat osteoporosis in Japan [3], but
there are no reports describing the effectiveness of weekly
TPTD injections for the treatment of BRONJ. Management of
BRONJ is challenging and controversial, and there is current-
ly no established drug treatment for this condition. We report
two patients with stage 3 BRONJ. One patient was success-
fully treated with weekly PTD injections, and the other with
daily TPTD injections. Changes in the levels of serum N-
telopeptide of type I collagen (s-NTX) and serum N-terminal
propeptide of type I collagen (P1NP) were studied.
Case reports
Case 1
An 87-year-old Japanese woman with a 4-year history of
alendronate therapy (35 mg/week orally) was referred for
the treatment of multiple fistulas with purulent discharge
over the left maxillary ridge. She was diagnosed with stage
3 BRONJ according to the AAOMS guidelines (2009). She
initially received conservative treatment, including instruc-
tion on oral hygiene, administration of antibiotics, antimi-
crobial mouth gargles, and local irrigation. N-BP therapy
was discontinued at the time of her first visit. Three months
later, she underwent sequestrectomy and extraction of the
maxillary left first and second molars because of high tooth
mobility (Fig. 1a, d, g). We continued conservative therapy
and debridement for 1 year. However, her disease was
persistent and progressive (Fig. 1b, e, h). She was then
treated with TPTD by subcutaneous injection (56.5 μg
weekly). After 3 months of TPTD treatment, there was
complete coverage of the necrotic tissue and exposed bone
with normal mucosa. Computed tomography showed that
her maxillary sinusitis attributed to stage 3 BRONJ had
resolved (Fig. 1c, f, i). Her s-NTX levels were slightly
higher than the pretreatment level at 1 and 3 months after
the initiation of TPTD treatment, and her serum P1NP level
decreased after the initiation of TPTD treatment (Fig. 1j).
Case 2
An 81-year-old Japanese woman with a 5-year history of
alendronate therapy (35 mg/week orally) was admitted for
the treatment of a pathological mandibular fracture. After
hospitalization, the teeth of the right mandible were natural-
ly detached after cutting the bridge; consecutively, metal
crowns were used. She was diagnosed with stage 3 BRONJ
and stopped her alendronate therapy after consultation with
her physician. She had infection of both the bone and soft
tissues (Fig. 2a, b, c). We advised surgical treatment, but this
was refused by the patient and her family. We administered
conservative treatment for BRONJ and the mandibular frac-
ture, including infection control and use of a chin cap to
limit movement of the jaw. After 2 months, her disease was
persistent and the fracture was still mobile. We started
TPTD treatment by subcutaneous injection (20 μg per
day). Three months later, her symptoms had resolved. The
osteonecrosis had healed and was covered by normal mu-
cosa. Computed tomography showed partial healing of the
mandibular fracture (Fig. 2d, e, f). Her s-NTX and P1NP
levels were low at the first visit. Her s-NTX levels were
slightly increased compared with the pretreatment level at 2
and 4 months after the initiation of TPTD treatment, and her
serum P1NP level was significantly increased at 2 months
after the initiation of TPTD treatment (Fig. 2g).
Discussion
BRONJ is a rare condition than can be debilitating. The
most frequent presentation of BRONJ is a small amount of
bare bone that is not painful or inflamed, which may heal
quickly, slowly, or not at all. Most cases are not as severe as
in the patients presented above. Recently, it has been sug-
gested that N-BP treatment may cause BRONJ [4]. BRONJ
is much more frequent in patients receiving intravenous N-
BP for the treatment and prevention of cancer-related skel-
etal conditions than in patients receiving oral N-BP for the
treatment of non-malignant disease [5]. BRONJ may be
associated with the type and total dose of N-BP treatment,
and with a history of trauma, dental surgery, and dental
infection [6]. We described an 87-year-old female with stage
3 BRONJ that persisted after control of the bone and soft
tissue infections, who required tooth extractions 3 months
after the withdrawal of N-BP treatment.
The main effects of N-BP are at the lumbar spine and
proximal femur, where they stop bone loss, reduce fracture
risk, and increase bone mineral density. Local trauma and
infection in the jaw increase the demand for bone repair,
which may exceed the low turnover rate of the bone, result-
ing in the accumulation of necrotic bone that is recognized
as osteonecrosis of the jaw.
There are some previous reports of TPTD treatment
in patients with osteonecrosis of the jaws associated
with N-BP therapy [7–9]. Additionally, several patients
treated with daily TPTD injections have now been
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reported, but the number of reports is limited and the
evidence to date is mostly anecdotal [10–12]. TPTD
injection is a unique pharmacological treatment for
patients with primary osteoporosis. TPTD treatment
stimulates bone formation and increase bone mineral
density [13]. TPTD may counteract the mechanisms
causing BRONJ by stimulating bone formation. An
increase in the number of remodeling units and in-
creased bone formation within each unit may promote
healing and the removal of damaged bone. In case 2,
the mandibular fracture and bone necrosis were success-
fully treated with daily TPTD injections, without the
need for surgery, which is similar to the patient reported by
Cheung and Seeman [8], who received the administration of
Fig. 1 Case 1. An 87-year-old Japanese woman with a 4-year history of
alendronate therapy. a At presentation, there were multiple fistulas with
purulent discharge over the left maxillary ridge (arrowheads). After
3 months of conservative therapy, the unhealed wound was surgically
debrided, and two teeth were extracted. bAfter 12months of conservative
treatment, there was still exposed bone in the upper jaw. cAfter 10 weeks
of teriparatide treatment, the necrotic bone had healed, and there was
complete soft tissue coverage of the intraoral wound. d, g Computed
tomography (CT) images showing the maxilla before tooth extraction and
debridement. e, h CT images after 1 year of conservative treatment,
showing expansion of the BRONJ area. f, i CT images after 10 weeks
teriparatide treatment, showing improvement of the maxillary sinusitis. j
Levels of serum N-telopeptide of type I collagen (s-NTX) and serum N-
terminal propeptide of type I collagen (P1NP)
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TPTD for osteonecrosis of the jaw in association with
alendronate therapy. In both our patients, TPTD treat-
ment was effective and achieved soft tissue coverage of
exposed bone. This is the first report describing suc-
cessful treatment of BRONJ with weekly TPTD
injections.
In conclusion, the outcomes of the cases presented
suggest that weekly TPTD injections can be effective
for the treatment of stage 3 BRONJ. If weekly and
daily TPTD injections are both effective, we can choose
the TPTD treatment regimen according to the condition
of the patient. In our patients, stage 3 BRONJ was
successfully treated by either weekly or daily TPTD
injections, thereby improving their quality of life. This
indicates that weekly TPTD injections might result in
resolution of stage 3 BRONJ by increasing the rate of
bone remodeling. Our data indicate that when it is
determined that a stage 3 BRONJ patient’s condition
does not improve under conservative therapy and there
are no other medical contraindications, daily, or weekly
TPTD treatment should be considered. Our data also
suggest that it may now be appropriate to initiate lim-
ited investigation of the response to weekly PTH treat-
ment, of uncomplicated stage 2 BRONJ cases with
persistent bare bone.
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